The Delta Variant Has Made Quest Diagnostics Indispensable

Nine months after the U.S. Food and Drug Administration (FDA) gave Pfizer (NYSE: PFE) and BioNTech's (NASDAQ: BNTX) COVID vaccine Emergency Use Authorization last December, testing remains important to managing the spread of COVID. This is especially the case with the circulation of the more contagious and deadly delta variant.

That's why Quest Diagnostics (NYSE: DGX) recently hiked its revenue and adjusted diluted earnings per share guidance for this year. But is the stock still a buy based on the current valuation?

Image source: Getty Images

Continue reading

Source Fool.com